HR+/HER2 Breast Cancer Palbociclib: Effective, simple, and safe

被引：0
|
作者：
Sonnet, Miriam
机构：
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [31] The optimal neoadjuvant treatment strategy for HR+/HER2 + breast cancer: a network meta-analysis
    Shiwei Liu
    Miao Yu
    Exian Mou
    Meihua Wang
    Shuanghua Liu
    Li Xia
    Hui Li
    Hao Tang
    Yajing Feng
    Xin Yu
    Kun Mi
    Hao Wang
    Scientific Reports, 15 (1)
  • [32] The prognostic impact of BMI in patients with HR+/HER2− advanced breast cancer: a study of the SONABRE registry
    Senna W. M. Lammers
    Hannah Thurisch
    Ingeborg J. H. Vriens
    Marissa Meegdes
    Sanne M. E. Engelen
    Frans L. G. Erdkamp
    M. Wouter Dercksen
    Birgit E. P. J. Vriens
    Kirsten N. A. Aaldering
    Manon J. A. E. Pepels
    Linda M. H. van de Winkel
    Natascha A. J. B. Peters
    Jolien Tol
    Joan B. Heijns
    Agnes J. van de Wouw
    Nathalie J. A. Teeuwen
    Sandra M. E. Geurts
    Vivianne C. G. Tjan-Heijnen
    Breast Cancer Research and Treatment, 2024, 203 : 339 - 349
  • [33] Real life efficacy of palbociclib and endocrine therapy in HR positive, HER2 negative advanced breast cancer
    Porte, Baptiste
    Carton, Matthieu
    Loirat, Delphine
    Bidard, Francois-Clement
    Haroun, Linda
    Bellesoeur, Audrey
    Kirova, Youlia
    Cottu, Paul
    CANCER RESEARCH, 2021, 81 (04)
  • [34] COMPARISON OF HER2 mRNA PCR LEVELS AND IMMUNOHISTOCHEMISTRY (IHC) IN HORMONE RECEPTOR POSITIVE (HR+)/HER2 NEGATIVE (HER2-) EARLY BREAST CANCER
    Tejerina-Peces, Julia
    Amann-Arevalo, Marta
    Ballestin, Pablo
    Gonzalez-Diez, Beatriz
    Paz-Cabezas, Mateo
    Pascual, Alejandro
    de Luna, Alicia
    Garcia-Barberan, Vanesa
    Lopez de Sa, Alfonso
    Garcia-Saenz, Jose Angel
    Moreno, Fernando
    CANCER RESEARCH, 2024, 84 (09)
  • [35] Real life efficacy of palbociclib and endocrine therapy in HR positive, HER2 negative advanced breast cancer
    Porte, B.
    Carton, M.
    Lerebours, F.
    Brain, E.
    Loirat, D.
    Haroun, L.
    Bellesoeur, A.
    Hamba, S. Bach
    Kirova, Y.
    Cottu, P.
    BREAST, 2020, 54 : 303 - 310
  • [36] REAL-WORLD DATA: IMPACT OF LOW HER-2 EXPRESSION IN METASTATIC HR+/HER2-BREAST CANCER TREATED WITH PALBOCICLIB
    Montenegro, Maria Alexandra
    Simao, Diana Cardoso
    Mendes, Jose Leao
    Fernandes, Leonor Raposo
    Martins, Maria Manuela
    Da Luz, Ricardo
    Oliveira, Sonia Duarte
    BREAST, 2023, 71 : S57 - S58
  • [37] SG Improves OS in HR+/HER2-Breast Cancer
    Poh, Alissa
    CANCER DISCOVERY, 2022, 12 (12) : 2714 - 2715
  • [38] Therapy of HR+/HER2-advanced or metastatic Breast Cancer Palbociclib: Importance of Data from Everyday Care for Therapy
    Ruedesheim, Sabine M.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (05)
  • [39] COST-EFFECTIVENESS OF PALBOCICLIB PLUS LETROZOLE IN THE TREATMENT OF HR+/HER2-ADVANCED OR METASTATIC BREAST CANCER IN ECUADOR
    Cabezas, M.
    Freire, V
    Salcedo, E.
    Albert, A.
    VALUE IN HEALTH, 2018, 21 : S32 - S32
  • [40] Pirfenidone inhibits CCL2-mediated Treg chemotaxis induced by palbociclib and fulvestrant in HR+/HER2-breast cancer
    Li, Siwei
    Zhang, Xianyu
    Pang, Da
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 142
12345